Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report)‘s stock had its “equal weight” rating reiterated by investment analysts at Wells Fargo & Company in a research note issued on Thursday, Marketbeat reports. They presently have a $19.00 price objective on the stock, down from their previous price objective of $30.00. Wells Fargo & Company‘s target price would indicate a potential upside of 12.63% from the company’s current price.
A number of other research firms have also weighed in on AMPH. Piper Sandler reaffirmed a “neutral” rating and issued a $21.00 price objective (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 11th. Jefferies Financial Group restated a “hold” rating and issued a $22.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, April 21st. Weiss Ratings lowered shares of Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, April 10th. Barclays lowered their target price on shares of Amphastar Pharmaceuticals from $30.00 to $23.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 8th. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Friday, May 8th. Seven investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Reduce” and an average target price of $24.50.
View Our Latest Stock Report on Amphastar Pharmaceuticals
Amphastar Pharmaceuticals Trading Down 2.5%
Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.28). Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. The company had revenue of $171.17 million during the quarter, compared to the consensus estimate of $173.46 million. Analysts predict that Amphastar Pharmaceuticals will post 2.93 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the stock. FNY Investment Advisers LLC bought a new position in Amphastar Pharmaceuticals in the 3rd quarter worth approximately $26,000. Global Retirement Partners LLC boosted its holdings in Amphastar Pharmaceuticals by 219.0% in the 3rd quarter. Global Retirement Partners LLC now owns 1,024 shares of the company’s stock worth $27,000 after buying an additional 703 shares during the period. Quarry LP bought a new position in Amphastar Pharmaceuticals in the 3rd quarter worth approximately $32,000. Farther Finance Advisors LLC boosted its holdings in Amphastar Pharmaceuticals by 46.3% in the 4th quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock worth $37,000 after buying an additional 437 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in Amphastar Pharmaceuticals by 37.8% in the 4th quarter. GAMMA Investing LLC now owns 1,685 shares of the company’s stock worth $45,000 after buying an additional 462 shares during the period. 65.09% of the stock is owned by institutional investors.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.
Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.
Read More
- Five stocks we like better than Amphastar Pharmaceuticals
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
